Department of Orthopedics, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu Province, People's Republic of China.
Anticancer Drugs. 2021 Feb 1;32(2):168-177. doi: 10.1097/CAD.0000000000000984.
We aimed to investigate the expression level of long noncoding RNA (lncRNA) zinc finger E-box-binding homeobox two antisense RNA 1 (ZEB2-AS1) in osteosarcoma and explore its possible regulatory mechanisms. Expression of lncRNA ZEB2-AS1 was detected by quantitative real-time PCR in 63 cancerous tissues and 25 adjacent normal mucosal tissues from patients with osteosarcoma. The correlation between the lncRNA ZEB2-AS1 level and clinicopathological characteristics of the osteosarcoma patients were evaluated, and 5-year overall survival (5OS) was also analyzed according to lncRNA ZEB2-AS1 expression. The ZEB2-AS1 and miR-145 recombinant expression vector was used to analyze their relationship in an in vitro cell system. Luciferase reporter gene assays and RNA immunoprecipitation assays were used to verify the interaction between ZEB2-AS1 and miR-145. The proliferation, apoptosis and migration of osteosarcoma cells were determined by Cell counting kit-8 assays, Annexin V-PI assays and transwell assays, respectively. A significantly increased level of lncRNA ZEB2-AS1 with a fold change of 3.86 was found in osteosarcoma tissues compared with control tissues (P < 0.001). The Chi-square test revealed that lncRNA ZEB2-AS1 expression in osteosarcoma was significantly different according to radiology classification (P = 0.018), TNM stage (P = 0.000) and survival status (P = 0.005). The 5OS was 18.4% and 52% in osteosarcoma patients with higher and lower lncRNA ZEB2-AS1 expression, respectively. Significantly increased ZEB2-AS1 expression was found in osteosarcoma cells, while decreased levels of miR-145 were confirmed in osteosarcoma tissues and cell lines compared to controls. Moreover, a negative correlation was found between the expression level of ZEB2-AS1 and miR-145 in osteosarcoma tissues (R2 = 0.71, P < 0.01). ZEB2-AS1 knockdown resulted in decreased osteosarcoma cell proliferation, increased apoptosis and reduced migration. In addition, negative regulation of miR-145 by ZEB2-AS1 in osteosarcoma cells was also observed, and the effects of ZEB2-AS1 on osteosarcoma cells were found to be regulated by miR-145. Significantly upregulated lncRNA ZEB2-AS1 expression in osteosarcoma patients influences the prognosis of patients, and ZEB2-AS1 accelerates tumorigenesis and osteosarcoma development by downregulating miR-145.
我们旨在研究骨肉瘤中长非编码 RNA(lncRNA)锌指 E 框结合同源盒 2 反义 RNA 1(ZEB2-AS1)的表达水平,并探讨其可能的调控机制。通过定量实时 PCR 检测 63 例骨肉瘤患者癌组织和 25 例癌旁正常黏膜组织中 lncRNA ZEB2-AS1 的表达。评估 lncRNA ZEB2-AS1 水平与骨肉瘤患者临床病理特征的相关性,并根据 lncRNA ZEB2-AS1 表达情况分析 5 年总生存率(5OS)。使用 ZEB2-AS1 和 miR-145 重组表达载体分析其在体外细胞系统中的关系。使用荧光素酶报告基因检测和 RNA 免疫沉淀检测验证 ZEB2-AS1 与 miR-145 之间的相互作用。通过细胞计数试剂盒-8 测定、Annexin V-PI 测定和 Transwell 测定分别确定骨肉瘤细胞的增殖、凋亡和迁移。与对照组织相比,骨肉瘤组织中 lncRNA ZEB2-AS1 的水平显著升高,倍数变化为 3.86(P < 0.001)。卡方检验显示,lncRNA ZEB2-AS1 在骨肉瘤中的表达根据影像学分类(P = 0.018)、TNM 分期(P = 0.000)和生存状态(P = 0.005)有显著差异。lncRNA ZEB2-AS1 高表达的骨肉瘤患者 5OS 为 18.4%,低表达的骨肉瘤患者 5OS 为 52%。与对照相比,骨肉瘤细胞中 ZEB2-AS1 的表达明显增加,而骨肉瘤组织和细胞系中 miR-145 的水平则降低。此外,骨肉瘤组织中 ZEB2-AS1 和 miR-145 的表达水平呈负相关(R2 = 0.71,P < 0.01)。ZEB2-AS1 敲低导致骨肉瘤细胞增殖减少、凋亡增加和迁移减少。此外,还观察到 ZEB2-AS1 对骨肉瘤细胞中 miR-145 的负调控,并且发现 ZEB2-AS1 对骨肉瘤细胞的作用是通过 miR-145 调节的。骨肉瘤患者中显著上调的 lncRNA ZEB2-AS1 表达影响患者的预后,并且 ZEB2-AS1 通过下调 miR-145 加速肿瘤发生和骨肉瘤的发展。